<DOC>
	<DOCNO>NCT00309205</DOCNO>
	<brief_summary>Approximately 36 HIV-negative woman , age &gt; 18 &lt; 50 , enrol study . Each volunteer 2:1 chance receive dapivirine gel versus placebo . The volunteer receive investigational product total 42 day .</brief_summary>
	<brief_title>A Safety Study Dapivirine ( TMC120 ) Vaginal Microbicide Gel Belgium</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>HIVnegative Willing participate sign informed consent form Willing test HIV , use experimental vaginal gel , randomize study group include possibility assign placebo group . Willing use two form contraception study Willing undergo pelvic examination colposcopy photographic documentation accord protocol throughout study . Have regular menstrual cycle define minimum 21 day maximum 36 day menses Currently pregnant breastfeed Clinically detectable genital abnormality vulva , vaginal wall cervix Laboratory confirm gonorrhea , chlamydia , trichomonas , syphilis , vaginal candidiasis clinically diagnose GUD active HSV2 lesion Breakthrough bleeding gynecologic surgery within 60 day prior randomization Symptomatic bacterial vaginosis Screening unwilling undergo treatment . Women require treatment tuberculosis ( TB ) within 21 day prior randomization .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>HIV seronegativity</keyword>
</DOC>